Fluoroquinolone resistance in uncomplicated acute pyelonephritis

Epidemiology and clinical impact

Jaehyun Shin, Jieun Kim, Seong Heon Wie, Young Kyun Cho, Seung Kwan Lim, Sang Yop Shin, Joon Sup Yeom, Jin Seo Lee, Ki Tae Kweon, Hyuck Lee, Hee-Jin Cheong, Sun Hee Park, Dae Won Park, Seong Yeol Ryu, Moon Hyun Chung, Sunmi Yoo, Hyunjoo Pai

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The objectives of this study were to investigate antibiotic resistance in urinary pathogens from Korean patients with uncomplicated acute pyelonephritis (UAPN), and to determine the effect of fluoroquinolone (FQ) resistance on clinical outcome in those patients with UAPN initially treated with FQ. Clinical and microbiologic data for all the APN patients attending 14 hospitals in South Korea in 2008 were collected retrospectively. Urinary pathogens were identified in 719 cases, and Escherichia coli was the most common pathogen (661/719, 91.9%). Antibiotic susceptibilities to several E. coli antibiotics were as follows: ciprofloxacin, 84.1%; trimethoprim-sulfamethoxazola (TMP-SMX), 67.2%; and extended-spectrum beta-lactamase-negative, 92.4%. FQ was the most frequent antibiotic prescribed for UAPN (45.3% intravenously and 53.9% by mouth). We compared clinical outcomes and hospital days in patients with FQ-resistant (32) and FQ-sensitive E. coli (173) who received FQ as initial empirical therapy. Clinical cure was higher in the FQ-sensitive group (78% vs. 91%, p=0.027), and hospital days were longer in the FQ-resistant group (9.6±5.5 days vs. 7±3.5 days, p=0.001). In conclusion, FQ-sensitivity of E. coli from UAPN was 84.1%. FQ treatment of UAPN caused by FQ-resistant E. coli has a lower cure rate and involves longer hospital stay than FQ treatment of cases caused by FQ-sensitive E. coli.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalMicrobial Drug Resistance
Volume18
Issue number2
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Pyelonephritis
Fluoroquinolones
Epidemiology
Escherichia coli
Anti-Bacterial Agents
Republic of Korea
Trimethoprim
beta-Lactamases
Ciprofloxacin
Microbial Drug Resistance
Mouth
Length of Stay
Therapeutics

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Pharmacology
  • Microbiology (medical)

Cite this

Shin, J., Kim, J., Wie, S. H., Cho, Y. K., Lim, S. K., Shin, S. Y., ... Pai, H. (2012). Fluoroquinolone resistance in uncomplicated acute pyelonephritis: Epidemiology and clinical impact. Microbial Drug Resistance, 18(2), 169-175. https://doi.org/10.1089/mdr.2011.0139

Fluoroquinolone resistance in uncomplicated acute pyelonephritis : Epidemiology and clinical impact. / Shin, Jaehyun; Kim, Jieun; Wie, Seong Heon; Cho, Young Kyun; Lim, Seung Kwan; Shin, Sang Yop; Yeom, Joon Sup; Lee, Jin Seo; Kweon, Ki Tae; Lee, Hyuck; Cheong, Hee-Jin; Park, Sun Hee; Park, Dae Won; Ryu, Seong Yeol; Chung, Moon Hyun; Yoo, Sunmi; Pai, Hyunjoo.

In: Microbial Drug Resistance, Vol. 18, No. 2, 01.04.2012, p. 169-175.

Research output: Contribution to journalArticle

Shin, J, Kim, J, Wie, SH, Cho, YK, Lim, SK, Shin, SY, Yeom, JS, Lee, JS, Kweon, KT, Lee, H, Cheong, H-J, Park, SH, Park, DW, Ryu, SY, Chung, MH, Yoo, S & Pai, H 2012, 'Fluoroquinolone resistance in uncomplicated acute pyelonephritis: Epidemiology and clinical impact', Microbial Drug Resistance, vol. 18, no. 2, pp. 169-175. https://doi.org/10.1089/mdr.2011.0139
Shin, Jaehyun ; Kim, Jieun ; Wie, Seong Heon ; Cho, Young Kyun ; Lim, Seung Kwan ; Shin, Sang Yop ; Yeom, Joon Sup ; Lee, Jin Seo ; Kweon, Ki Tae ; Lee, Hyuck ; Cheong, Hee-Jin ; Park, Sun Hee ; Park, Dae Won ; Ryu, Seong Yeol ; Chung, Moon Hyun ; Yoo, Sunmi ; Pai, Hyunjoo. / Fluoroquinolone resistance in uncomplicated acute pyelonephritis : Epidemiology and clinical impact. In: Microbial Drug Resistance. 2012 ; Vol. 18, No. 2. pp. 169-175.
@article{73da4326dfa04d29b3da5894be947885,
title = "Fluoroquinolone resistance in uncomplicated acute pyelonephritis: Epidemiology and clinical impact",
abstract = "The objectives of this study were to investigate antibiotic resistance in urinary pathogens from Korean patients with uncomplicated acute pyelonephritis (UAPN), and to determine the effect of fluoroquinolone (FQ) resistance on clinical outcome in those patients with UAPN initially treated with FQ. Clinical and microbiologic data for all the APN patients attending 14 hospitals in South Korea in 2008 were collected retrospectively. Urinary pathogens were identified in 719 cases, and Escherichia coli was the most common pathogen (661/719, 91.9{\%}). Antibiotic susceptibilities to several E. coli antibiotics were as follows: ciprofloxacin, 84.1{\%}; trimethoprim-sulfamethoxazola (TMP-SMX), 67.2{\%}; and extended-spectrum beta-lactamase-negative, 92.4{\%}. FQ was the most frequent antibiotic prescribed for UAPN (45.3{\%} intravenously and 53.9{\%} by mouth). We compared clinical outcomes and hospital days in patients with FQ-resistant (32) and FQ-sensitive E. coli (173) who received FQ as initial empirical therapy. Clinical cure was higher in the FQ-sensitive group (78{\%} vs. 91{\%}, p=0.027), and hospital days were longer in the FQ-resistant group (9.6±5.5 days vs. 7±3.5 days, p=0.001). In conclusion, FQ-sensitivity of E. coli from UAPN was 84.1{\%}. FQ treatment of UAPN caused by FQ-resistant E. coli has a lower cure rate and involves longer hospital stay than FQ treatment of cases caused by FQ-sensitive E. coli.",
author = "Jaehyun Shin and Jieun Kim and Wie, {Seong Heon} and Cho, {Young Kyun} and Lim, {Seung Kwan} and Shin, {Sang Yop} and Yeom, {Joon Sup} and Lee, {Jin Seo} and Kweon, {Ki Tae} and Hyuck Lee and Hee-Jin Cheong and Park, {Sun Hee} and Park, {Dae Won} and Ryu, {Seong Yeol} and Chung, {Moon Hyun} and Sunmi Yoo and Hyunjoo Pai",
year = "2012",
month = "4",
day = "1",
doi = "10.1089/mdr.2011.0139",
language = "English",
volume = "18",
pages = "169--175",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Fluoroquinolone resistance in uncomplicated acute pyelonephritis

T2 - Epidemiology and clinical impact

AU - Shin, Jaehyun

AU - Kim, Jieun

AU - Wie, Seong Heon

AU - Cho, Young Kyun

AU - Lim, Seung Kwan

AU - Shin, Sang Yop

AU - Yeom, Joon Sup

AU - Lee, Jin Seo

AU - Kweon, Ki Tae

AU - Lee, Hyuck

AU - Cheong, Hee-Jin

AU - Park, Sun Hee

AU - Park, Dae Won

AU - Ryu, Seong Yeol

AU - Chung, Moon Hyun

AU - Yoo, Sunmi

AU - Pai, Hyunjoo

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The objectives of this study were to investigate antibiotic resistance in urinary pathogens from Korean patients with uncomplicated acute pyelonephritis (UAPN), and to determine the effect of fluoroquinolone (FQ) resistance on clinical outcome in those patients with UAPN initially treated with FQ. Clinical and microbiologic data for all the APN patients attending 14 hospitals in South Korea in 2008 were collected retrospectively. Urinary pathogens were identified in 719 cases, and Escherichia coli was the most common pathogen (661/719, 91.9%). Antibiotic susceptibilities to several E. coli antibiotics were as follows: ciprofloxacin, 84.1%; trimethoprim-sulfamethoxazola (TMP-SMX), 67.2%; and extended-spectrum beta-lactamase-negative, 92.4%. FQ was the most frequent antibiotic prescribed for UAPN (45.3% intravenously and 53.9% by mouth). We compared clinical outcomes and hospital days in patients with FQ-resistant (32) and FQ-sensitive E. coli (173) who received FQ as initial empirical therapy. Clinical cure was higher in the FQ-sensitive group (78% vs. 91%, p=0.027), and hospital days were longer in the FQ-resistant group (9.6±5.5 days vs. 7±3.5 days, p=0.001). In conclusion, FQ-sensitivity of E. coli from UAPN was 84.1%. FQ treatment of UAPN caused by FQ-resistant E. coli has a lower cure rate and involves longer hospital stay than FQ treatment of cases caused by FQ-sensitive E. coli.

AB - The objectives of this study were to investigate antibiotic resistance in urinary pathogens from Korean patients with uncomplicated acute pyelonephritis (UAPN), and to determine the effect of fluoroquinolone (FQ) resistance on clinical outcome in those patients with UAPN initially treated with FQ. Clinical and microbiologic data for all the APN patients attending 14 hospitals in South Korea in 2008 were collected retrospectively. Urinary pathogens were identified in 719 cases, and Escherichia coli was the most common pathogen (661/719, 91.9%). Antibiotic susceptibilities to several E. coli antibiotics were as follows: ciprofloxacin, 84.1%; trimethoprim-sulfamethoxazola (TMP-SMX), 67.2%; and extended-spectrum beta-lactamase-negative, 92.4%. FQ was the most frequent antibiotic prescribed for UAPN (45.3% intravenously and 53.9% by mouth). We compared clinical outcomes and hospital days in patients with FQ-resistant (32) and FQ-sensitive E. coli (173) who received FQ as initial empirical therapy. Clinical cure was higher in the FQ-sensitive group (78% vs. 91%, p=0.027), and hospital days were longer in the FQ-resistant group (9.6±5.5 days vs. 7±3.5 days, p=0.001). In conclusion, FQ-sensitivity of E. coli from UAPN was 84.1%. FQ treatment of UAPN caused by FQ-resistant E. coli has a lower cure rate and involves longer hospital stay than FQ treatment of cases caused by FQ-sensitive E. coli.

UR - http://www.scopus.com/inward/record.url?scp=84859593125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859593125&partnerID=8YFLogxK

U2 - 10.1089/mdr.2011.0139

DO - 10.1089/mdr.2011.0139

M3 - Article

VL - 18

SP - 169

EP - 175

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 2

ER -